Jiang Zhong Pharmaceutical Co.,Ltd

SHSE:600750 Stock Report

Market Cap: CN¥12.6b

Jiang Zhong PharmaceuticalLtd Past Earnings Performance

Past criteria checks 4/6

Jiang Zhong PharmaceuticalLtd has been growing earnings at an average annual rate of 10.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 15.3% per year. Jiang Zhong PharmaceuticalLtd's return on equity is 19.4%, and it has net margins of 18.2%.

Key information

10.8%

Earnings growth rate

10.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate15.3%
Return on equity19.4%
Net Margin18.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) Analysts Just Slashed This Year's Revenue Estimates By 11%

Sep 12
Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) Analysts Just Slashed This Year's Revenue Estimates By 11%

Lacklustre Performance Is Driving Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Low P/E

Jul 20
Lacklustre Performance Is Driving Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Low P/E

A Look At The Fair Value Of Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750)

May 22
A Look At The Fair Value Of Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750)

Why Investors Shouldn't Be Surprised By Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Low P/E

Apr 15
Why Investors Shouldn't Be Surprised By Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Low P/E

Revenue & Expenses Breakdown

How Jiang Zhong PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:600750 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,1257501,620140
30 Jun 244,2017471,693153
31 Mar 244,2737331,730135
31 Dec 234,3907081,837133
30 Sep 234,2486861,85798
30 Jun 234,3466561,967102
31 Mar 234,2996571,91499
31 Dec 223,8855981,715100
30 Sep 223,8115591,713113
30 Jun 223,5095911,49499
31 Mar 223,1275301,33896
31 Dec 212,8745061,19688
30 Sep 212,6445281,07070
30 Jun 212,5495101,02866
31 Mar 212,5945021,03866
31 Dec 202,44147496456
30 Sep 202,48148099751
30 Jun 202,46748297650
31 Mar 202,4374681,01346
31 Dec 192,4494641,03348
30 Sep 192,16749881445
30 Jun 192,00149472841
31 Mar 191,83248162336
31 Dec 181,75547059730
30 Sep 181,73145062926
30 Jun 181,76443665831
31 Mar 181,77842569827
31 Dec 171,74741868123
30 Sep 171,76443865612
30 Jun 171,5553865910
31 Mar 171,4973745610
31 Dec 161,5483726360
30 Sep 161,8054016510
30 Jun 162,1504247310
31 Mar 162,4554118090
31 Dec 152,5973677950
30 Sep 152,6643328390
30 Jun 152,7633089420
31 Mar 152,7572759730
31 Dec 142,8342651,0460
30 Sep 142,9521881,1230
30 Jun 142,8721541,0340
31 Mar 142,8291429450
31 Dec 132,7781728130

Quality Earnings: 600750 has high quality earnings.

Growing Profit Margin: 600750's current net profit margins (18.2%) are higher than last year (16.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600750's earnings have grown by 10.8% per year over the past 5 years.

Accelerating Growth: 600750's earnings growth over the past year (9.4%) is below its 5-year average (10.8% per year).

Earnings vs Industry: 600750 earnings growth over the past year (9.4%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 600750's Return on Equity (19.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies